Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.
|Number of pages||4|
|Journal||International Journal of Clinical Pharmacology and Therapeutics|
|Publication status||Published - 2012 May|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)